CRX-100 is under clinical development by BioEclipse Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CRX-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CRX-100 overview
CRX-100 is under development for the treatment of solid tumors such as malignant melanoma, non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, osteosarcoma, epithelial ovarian cancer, gastric cancer. It is administered by intravenous route. The drug candidate is made up of two components. It is a combination immunotherapy which combines immune cells that incorporated with a Vaccinia virus to protect the oncolytic agent from destruction by the immune system. It was also under development for prostate, Non-Hodgkin’s lymphoma, glioblastoma and neuroblastoma.
BioEclipse Therapeutics overview
BioEclipse Therapeutics formerly ConcentRx, Inc., is a clinical-stage oncology company that uses platform technology to develop immuno-oncology therapeutics. The company’s lead product candidate, CRX-100, a combined immunotherapy designed to target and kill cancer cells throughout the body while triggering an immune response that may prevent relapse. It targets epithelial ovarian cancer, melanoma, non-small cell lung cancer, triple negative breast, gastric cancer, hepatocellular carcinoma, osteosarcoma and colorectal. BioEclipse Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of CRX-100’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
